Wu Xiaobin's Form 4 filing
BeOne Medicines Ltd. (ONC) · filed Jun 15, 2026
- Accession no.
- 0001739452-26-000006
- Filed
- Jun 15, 2026
- Trade date
- Jun 11, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $163.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wu XiaobinCIK 0001739452 | Officer (President and COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | Ordinary Shares | AGrant or awardAcquired | +118,625 | $0.00 | $0 | 1,308,161 | Direct | |
| Jun 11, 2026 | American Depositary Shares | SSaleDisposed | −626 | $261.20F4 | −$163,511.2 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | Ordinary Shares | AGrant or awardAcquired | +229,775 | $0.00 | $0 | 229,775 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.19 to $261.29, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.